CSL Limited

From Wikipedia, the free encyclopedia

CSL Limited
Type Public
ASX: CSL
Founded 1994 (privatised), 1916 (government department)
Headquarters Melbourne, Australia
Key people Brian A McNamee (CEO)
Industry medicine
Products blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue $1,500 million AUD (Y.E. 30 June 2004)
Website www.csl.com.au

CSL Limited is an Australian-based manufacturer of medical products. Its products include various blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing.

Contents

[edit] History

Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. The operation commenced plasma fractionation in 1952. It was privatised as CSL Ltd in 1994. In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring.

[edit] Locations

The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne. CSL Behring is headquartered in King of Prussia, Pennsylvania and has manufacturing operations in the Swiss city of Berne, in Marburg in Germany, and Kankakee, Illinois.

[edit] Ownership

CSL is a public company whose stock is traded on the Australian Stock Exchange under the stock code CSL. The company completed an Initial Public Offering in June 1994 at A$2.30 per share. Today CSL stock is part of the S&P/ASX 50 Index.

[edit] Products

CSL Limited's products can be separated by company division. Some of the key products produced by each division, circa 2006, include:

[edit] CSL Vaccines

[edit] Vaccines

[edit] Antivenoms

[edit] CSL Pharmaceuticals

[edit] CSL Behring

  • Beriate, which is freeze-dried human factor VIII concentrate
  • Berinin, freeze-dried human factor IX concentrate
  • Helixate FS, freeze-dried recombinant coagulation factor VIII. CSL is working on a new Helixate product called "Helixate NexGen".
  • Humate-P, freeze-dried human coagulation factor VIII/von Willebrand factor complex
  • Monoclate, a freeze-dried human coagulation factor VIII that has been purified using monoclonal antibodies
  • Mononine, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
  • Stimate, a synthetic desmopressin acetate nasal spray

[edit] CSL Bioplasma

[edit] See also